Travoprost: how does it work?

Article

Travoprost appears to lower intraocular pressure (IOP) by increasing trabecular outflow facility, although an effect on uvoescleral outflow cannot be ruled out, according to a study published in the March issue of the Journal of Glaucoma.

Travoprost appears to lower intraocular pressure (IOP) by increasing trabecular outflow facility, although an effect on uvoescleral outflow cannot be ruled out, according to a study published in the March issue of the Journal of Glaucoma.

Carol Toris and colleagues from the University of Nebraska Medical Center, USA, conducted a study to determine the mechanism by which travoprost 0.004% reduces IOP in patients with ocular hypertension or primary open angle glaucoma. The randomized, double-masked, placebo-controlled, single centre study enrolled 26 subjects.

After a washout of all medications, baseline IOPs were recorded and travoprost 0.004% was administered once-daily in the evening for 17 consecutive days to one eye and its vehicle to the fellow eye in a randomized, masked fashion. On day 15, twelve hours after the 14th dose, IOP was measured by pneumatonometry, aqueous flow and outflow facility by fluorophotometry and episcleral venous pressure by venomanometry. Uveoscleral outflow was determined by mathematical calculation. Two days later, the last drop was administered and fluorophotometry and tonometry measurements were repeated.

Eyes treated with travoprost demonstrated a significant decrease in daytime IOP (p<0.001) compared with baseline (26%) or to vehicle-treated eyes (22%), in addition to an increase in daytime outflow facility (p=0.001; 64%). The increase in uveoscleral outflow was not statistically significant. At night, travoprost-treated eyes remained 21-24% below baseline daytime values. Aqueous outflow was significantly reduced at night (p<0.001) in both travoprost (30%) and vehicle-treated eyes (25%) when compared with daytime values.

The researchers believe that travoprost works by increasing trabecular outflow facility, however, an effect on uveoscleral outflow cannot be ruled out.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.